AEON Biopharma to Present ABP-450 Biosimilar Data at 2026 AAN Meeting

Event summary

  • AEON Biopharma's abstract on ABP-450 (prabotulinumtoxinA) accepted for poster presentation at the 2026 AAN Annual Meeting in Chicago, April 18-22.
  • Presentation details primary structure comparability between ABP-450 and BOTOX®, supporting biosimilarity claims.
  • AEON's ABP-450 is already approved as a biosimilar in India, Mexico, and the Philippines.
  • U.S. therapeutic neurotoxin market exceeds $3.0 billion annually.

The big picture

AEON Biopharma's presentation at the AAN Annual Meeting underscores its strategic push to establish ABP-450 as a viable biosimilar to BOTOX® in the lucrative U.S. neurotoxin market. The company is leveraging analytical similarity data to support its biosimilarity claims, a critical step in the FDA's approval process. Success here could position AEON as a significant player in a market dominated by established brands, potentially disrupting the competitive landscape.

What we're watching

Regulatory Pathway
Whether AEON can navigate the FDA's 351(k) biosimilar pathway efficiently to achieve accelerated U.S. market entry.
Market Competition
How AEON's ABP-450 will compete against Evolus' Jeuveau® and other established neurotoxin products in the U.S.
Clinical Validation
The pace at which AEON can accumulate clinical and regulatory data to support full-label access in the U.S.